Unity Biotechnology, Inc. - UBX STOCK NEWS

UNITY Biotechnology (NASDAQ: UBX) will present a corporate update at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 11:10 a.m. ET. The event will be virtual, and a replay will be accessible for 90 days afterward. UNITY focuses on developing therapeutics aimed at slowing, halting, or reversing diseases associated with aging, particularly in age-related ophthalmologic and neurologic conditions. Interested investors can access the presentation through the Cowen conference portal or their website.

UNITY Biotechnology presented 24-week Phase 1 data for UBX1325 at the Angiogenesis, Exudation, and Degeneration 2022 conference. The study involved patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), showing significant improvements in visual acuity. Key findings include a mean improvement of 9.5 ETDRS letters for DME patients and stabilization in wAMD. UBX1325 was well tolerated, with no significant ocular adverse effects. Phase 2 trials for both conditions are currently underway, with preliminary results expected in mid-2022.

UNITY Biotechnology, Inc. (UBX) announced a strategic restructuring to focus on its ophthalmology clinical programs, particularly the UBX1325 studies, extending its cash runway into Q1 2023. Key data readouts from the Phase 2a study in diabetic macular edema and the Phase 2 study in wet age-related macular degeneration are expected in mid and late 2022, respectively. The workforce will be reduced by approximately 50%, refocusing efforts on more advanced programs to optimize resource allocation.

UNITY Biotechnology, Inc. (NASDAQ: UBX) has announced the grant of a stock-based award covering 2,750 shares to a new employee from January 18 to February 1, 2022. This award, part of the UNITY 2020 Employment Inducement Incentive Plan, aims to incentivize newly hired employees according to Nasdaq rules. UNITY focuses on developing therapeutics to combat age-related diseases by targeting senescent cells, with current efforts in ophthalmologic and neurologic conditions.

UNITY Biotechnology announced the design for its Phase 2 study of UBX1325 targeting wet age-related macular degeneration (AMD) with initial data expected in H2 2022. The study will compare UBX1325 against aflibercept and assess safety and efficacy. Additionally, the company plans to share 12-week safety data from a Phase 2 study in diabetic macular edema (DME) in the first half of 2022. The investigational drug UBX1325 is designed for age-related eye diseases and aims to improve patient outcomes.

UNITY Biotechnology, Inc. (NASDAQ: UBX) announced on December 22, 2021, that its Compensation Committee granted a stock-based award to a new employee from December 7 to December 21, 2021. This award includes options to purchase a total of 4,500 shares of UNITY common stock. The award follows the UNITY 2020 Employment Inducement Incentive Plan, which aims to attract new employees as per Nasdaq Rule 5635(c)(4).

UNITY focuses on developing therapeutics to combat age-related diseases, targeting senescent cells to improve health outcomes in ophthalmologic and neurologic conditions.

UNITY Biotechnology has entered an exclusive licensing agreement with Jocasta Neuroscience for its α-Klotho asset aimed at treating cognitive disorders. This deal enables UNITY to receive an upfront payment and additional milestone payments based on development and sales. The α-Klotho protein has shown promise in preclinical studies for improving cognitive performance, potentially counteracting Alzheimer’s disease symptoms. UNITY will focus on advancing its leading program, UBX1325, while benefiting economically from α-Klotho's development.

UNITY Biotechnology (UBX) reported Q3 2021 financial results, highlighting favorable outcomes from the Phase 1 study of UBX1325, a novel senolytic therapy. The Phase 1 trial demonstrated a favorable safety profile and biological activity over six months. Currently, a Phase 2 study for diabetic macular edema (DME) is enrolling patients, with a second Phase 2 study in age-related macular degeneration (AMD) anticipated in H1 2022. As of September 30, 2021, cash equivalents totaled $88.5 million, sufficient to sustain operations through Q3 2022.

UNITY Biotechnology announced promising results from its Phase 1 trial of UBX1325, targeting diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Patients in higher dose cohorts with DME gained an average of 9.5 ETDRS letters in visual acuity over 24 weeks post-injection. For wet AMD, visual improvements were noted at 12 weeks. The treatment was well-tolerated with no significant side effects. UNITY plans to advance UBX1325 into Phase 2 studies for both conditions in 2022, expecting crucial safety and efficacy data next year.